Software that tells physicians what a ventilated patient's lungs are actually doing.

Romulus (ROM) is a software add-on for mechanical ventilators — non-invasive, data-driven, built on six years of biomedical engineering research — giving physicians earlier, better-informed treatment decisions.

↓ Our story, from research to roadmap

The founders

Andy Keymolen and Antoine Marchal each dedicated their PhD in biomedical engineering to improving invasive mechanical ventilation, and have worked together on this problem for six years.

Antoine Marchal

Antoine Marchal

Technical lead

Mathematical models, machine learning, software. Leads operations & quality.

Andy Keymolen

Andy Keymolen

Project delivery lead

Fund-raising, clinical trials, regulatory affairs, IP, and physician networking. Led the research.

From research to the field

Every milestone we've hit, and the ones we're working toward next — scroll to move forward in time.

Achieved
Research foundation

Six years of dedicated PhD research

Both founders dedicated their PhD in biomedical engineering to improving invasive mechanical ventilation — the research foundation Romulus is built on.

Achieved
Clinical proof-of-concept

21-patient pilot with Demcon, a ventilator OEM

Run together with Demcon on 21 ICU patients — physicians are confident the approach can reduce mechanical-ventilator weaning failures by 33%.

Achieved
Grant awarded

€1M grant to fund two further clinical trials

Awarded on the strength of the pilot data — independent validation from grant reviewers, not just our own assessment.

Achieved
First customer

NDA signed with Demcon

Our proof-of-concept partner is now under NDA for further integration work toward a full product integration.

Achieved
Market validation

4 ICU departments express interest

Halle, UZ Leuven, Brugmann, and UZ Brussel have given written expressions of interest in evaluating Romulus.

Next
2027

CT1 — pivotal clinical trial

Our pivotal trial, integrating a second signal (sEMG / diaphragm activity) alongside our existing pressure-based measurement.

Milestone
2027

QMS build & MDR certification underway

Regulatory and quality-management-system work runs in parallel with the pivotal trial, toward OEM-level MDR certification.

Next
2027–2028

First commercial contracts & implementation

Targeting signed sales contracts and a first field implementation with our early ICU partners.

Next
2028–2029

CT2 — patient-outcome trial

A second clinical trial validating patient-outcome benefit across our combined pressure + sEMG measurement.

Milestone
2029

First device in the field

Our respiratory-mechanics feature reaches its first ICU patients in daily clinical use.

Later
2029–2030

Diaphragm-monitoring feature

Building on preliminary CT2 data, extending Romulus to diaphragm-activity monitoring.

Vision
2030s

Platform expansion — cloud & home monitoring

A cloud-based, multi-signal platform, extending from the ICU to home respiratory monitoring.